Accuray Incorporated (ARAY) Drops 7.24% on January 29

Equities Staff |

Accuray Incorporated (ARAY) was one of the Russell 2000's biggest losers for Friday January 29 as the stock slid 7.24% to $5.38, a loss of $-0.4199 per share. Starting at an opening price of $5.47 a share, the stock traded between $5.14 and $5.64 over the course of the trading day. Volume was 1.68 million shares over 9,273 trades, against an average daily volume of 825,008 shares and a total float of 79.87 million.

The losses send Accuray Incorporated down to a market cap of $429.71 million. In the last year, Accuray Incorporated has traded between $10.01 and $4.80, and its 50-day SMA is currently $6.53 and 200-day SMA is $6.56.

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Incorporated is based out of Sunnyvale, CA and has some 1,010 employees. Its CEO is Joshua H. Levine.

For a complete fundamental analysis analysis of Accuray Incorporated, check out’s Stock Valuation Analysis report for ARAY. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…